ArticleJACS Au2026
ProMol_Func: A Structure-Free Deep Learning Model for Virtual Screening.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In computational-aided drug discovery, structure-based drug design models are computationally intensive and rely on protein structures, limiting their scalability and generalization. Additionally, many existing models suffer from inflated false-positive rates due to the scarcity of negative binding data for training. To overcome these challenges, we present ProMol_Func, a structure-free deep learning framework that integrates graph-based encodings of small molecules with protein function embeddings derived solely from amino acid sequences. By augmenting the training data set with both experimentally validated inactives and randomly selected decoys, ProMol_Func improves screening power and generalization. The model achieves state-of-the-art performance on the challenging LIT-PCBA (Library of Integrated Targeted-Panel of Cell-Based Assays) benchmark, with an enrichment factor (EF1%) of 10.9, demonstrating robust screening power in realistic assay settings. Furthermore, in a zero-shot prospective application to
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.